東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Characterization of Potential Mechan...

Iqbal, Farwah.

Linked to FindBook

Google Book

Amazon

博客來

Characterization of Potential Mechanisms That Render the Combination of First Trimester Umbilical Cord-derived Perivascular Cells (FTM HUCPVC) and Endothelial Progenitor Cells (EPC) a Promising Cellular Therapeutic Strategy Following Ischemic Cardiac Injury.

Record Type:	Electronic resources : Monograph/item
Title/Author:	Characterization of Potential Mechanisms That Render the Combination of First Trimester Umbilical Cord-derived Perivascular Cells (FTM HUCPVC) and Endothelial Progenitor Cells (EPC) a Promising Cellular Therapeutic Strategy Following Ischemic Cardiac Injury./
Author:	Iqbal, Farwah.
Published:	Ann Arbor : ProQuest Dissertations & Theses, : 2019,
Description:	354 p.
Notes:	Source: Dissertations Abstracts International, Volume: 81-06, Section: B.
Contained By:	Dissertations Abstracts International81-06B.
Subject:	Therapy. -
Online resource:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=22622786
ISBN:	9781392840665

Characterization of Potential Mechanisms That Render the Combination of First Trimester Umbilical Cord-derived Perivascular Cells (FTM HUCPVC) and Endothelial Progenitor Cells (EPC) a Promising Cellular Therapeutic Strategy Following Ischemic Cardiac Injury.
Iqbal, Farwah.

Characterization of Potential Mechanisms That Render the Combination of First Trimester Umbilical Cord-derived Perivascular Cells (FTM HUCPVC) and Endothelial Progenitor Cells (EPC) a Promising Cellular Therapeutic Strategy Following Ischemic Cardiac Injury. - Ann Arbor : ProQuest Dissertations & Theses, 2019 - 354 p.

Source: Dissertations Abstracts International, Volume: 81-06, Section: B.

Thesis (Ph.D.)--University of Toronto (Canada), 2019.

This item must not be sold to any third party vendors.

Heart disease is the main cause of mortality worldwide. The available treatments are limited, high risk and often inefficient. Cell-based therapies are being developed to provide an efficient and safe option to improve quality of life, prevent future mortality and the need for heart transplantation. Aged and ill individuals often have impaired endogenous regenerative cells. Instead, healthy, young cells can be delivered into the damaged heart to decrease inflammation, restore blood flow, preserve the myocardium and increase cardiac output. Pre-clinically and clinically tested therapeutic cell types achieved some of these goals, but no single-cell type seems to be versatile enough, to heal the heart on its own. Herein, I propose the combined use of two regenerative cell types as a treatment after myocardial infarction (MI). The first cell type is the endothelial progenitor cell (EPC), which are the origin of new blood vessels, second is the first trimester human umbilical cord-derived perivascular cell (FTM HUCPVC). FTM HUCPVC can support developing blood vessels, control inflammation and release growth factors. We hypothesized that combined administration of these cells can achieve clinically significant healing in a damaged heart. We previously found that FTM HUCPVC have greater regenerative potential following cardiac injury compared to term HUCPVC and bone marrow-derived mesenchymal stem cells. Optimal cell ratios were determined by a mouse model of subcutaneous angiogenesis and an immunocompromised rat model of MI. The combination of FTM HUCPVC and EPC significantly improved vasculogenesis compared to single cell-type treatments partly through the platelet-derived growth factor beta (PDGF-B) signalling cascade. Both FTM HUCPVC and EPC in combination support perivascular niches in the myocardium by homing to vascular structures and secreting pro-angiogenic factors. The resultant cardiac perfusion is likely required for cardiac muscle preservation, scar tissue reduction, and ultimately the improved cardiac function. To our knowledge, this study is the first to show significant structural and functional cardiac improvements following combination cell therapy compared to single cell-type therapies.Currently our group is working on large animal studies to test this novel therapeutic approach as we plan for a phase I clinical trial to provide a novel treatment option for patients following MI.

ISBN: 9781392840665Subjects--Topical Terms:

3343697
Therapy.
Subjects--Index Terms:

Angiogenesis

Characterization of Potential Mechanisms That Render the Combination of First Trimester Umbilical Cord-derived Perivascular Cells (FTM HUCPVC) and Endothelial Progenitor Cells (EPC) a Promising Cellular Therapeutic Strategy Following Ischemic Cardiac Injury.
LDR:03816nmm a2200361 4500 001 2272796
005 20201105110226.5
008 220629s2019 ||||||||||||||||| ||eng d
020 $a 9781392840665
035 $a (MiAaPQ)AAI22622786
035 $a AAI22622786
040 $a MiAaPQ $c MiAaPQ
100 1 $a Iqbal, Farwah. $3 3550222
245 1 0 $a Characterization of Potential Mechanisms That Render the Combination of First Trimester Umbilical Cord-derived Perivascular Cells (FTM HUCPVC) and Endothelial Progenitor Cells (EPC) a Promising Cellular Therapeutic Strategy Following Ischemic Cardiac Injury.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2019
300 $a 354 p.
500 $a Source: Dissertations Abstracts International, Volume: 81-06, Section: B.
500 $a Advisor: Librach, Clifford;Li, Ren-Ke.
502 $a Thesis (Ph.D.)--University of Toronto (Canada), 2019.
506 $a This item must not be sold to any third party vendors.
520 $a Heart disease is the main cause of mortality worldwide. The available treatments are limited, high risk and often inefficient. Cell-based therapies are being developed to provide an efficient and safe option to improve quality of life, prevent future mortality and the need for heart transplantation. Aged and ill individuals often have impaired endogenous regenerative cells. Instead, healthy, young cells can be delivered into the damaged heart to decrease inflammation, restore blood flow, preserve the myocardium and increase cardiac output. Pre-clinically and clinically tested therapeutic cell types achieved some of these goals, but no single-cell type seems to be versatile enough, to heal the heart on its own. Herein, I propose the combined use of two regenerative cell types as a treatment after myocardial infarction (MI). The first cell type is the endothelial progenitor cell (EPC), which are the origin of new blood vessels, second is the first trimester human umbilical cord-derived perivascular cell (FTM HUCPVC). FTM HUCPVC can support developing blood vessels, control inflammation and release growth factors. We hypothesized that combined administration of these cells can achieve clinically significant healing in a damaged heart. We previously found that FTM HUCPVC have greater regenerative potential following cardiac injury compared to term HUCPVC and bone marrow-derived mesenchymal stem cells. Optimal cell ratios were determined by a mouse model of subcutaneous angiogenesis and an immunocompromised rat model of MI. The combination of FTM HUCPVC and EPC significantly improved vasculogenesis compared to single cell-type treatments partly through the platelet-derived growth factor beta (PDGF-B) signalling cascade. Both FTM HUCPVC and EPC in combination support perivascular niches in the myocardium by homing to vascular structures and secreting pro-angiogenic factors. The resultant cardiac perfusion is likely required for cardiac muscle preservation, scar tissue reduction, and ultimately the improved cardiac function. To our knowledge, this study is the first to show significant structural and functional cardiac improvements following combination cell therapy compared to single cell-type therapies.Currently our group is working on large animal studies to test this novel therapeutic approach as we plan for a phase I clinical trial to provide a novel treatment option for patients following MI.
590 $a School code: 0779.
650 4 $a Therapy. $3 3343697
650 4 $a Cellular biology. $3 3172791
653 $a Angiogenesis
653 $a Cellular-based Therapy
653 $a Human Umbilical Cord Perivascular Cells
653 $a Mesenchymal Stem Cells
653 $a Myocardial Infarction
690 $a 0212
690 $a 0379
710 2 $a University of Toronto (Canada). $b Physiology. $3 3285885
773 0 $t Dissertations Abstracts International $g 81-06B.
790 $a 0779
791 $a Ph.D.
792 $a 2019
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=22622786